Cancer
Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom
Value in Health. 2017; 20(9):A427
Authors
Bermingham S, Schmid P, Forster F, Cornic L, Theti D, Smith A
Noteworthy
This is the first study to estimate the progression-related indirect and societal costs of HR+/HER2- metastatic breast cancer in the UK.
We developed a novel method to systematically search and screen both journal articles and grey literature.
Process
Systematic search of journal articles and grey literature reporting indirect costs associated with metastatic breast cancer (early mortality, productivity loss, replacement housework, childcare, informal care, lost leisure time,
and transportation).
Critical appraisal and extraction of relevant resource use estimates from the UK and other countries.
Costs were estimated per woman, per month, for two ‘health states’: stable and progressed disease.
Publications in other disease areas
Atrial fibrillation
Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke
Cancer
Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom
Idiopathic pulmonary fibrosis
The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review
Psoriasis
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis
Rheumatoid arthritis
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK
Venous thromboembolism
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective